Verily Life Sciences
Verily Life Sciences raises $1B Series D at $6B valuation
Quick Facts
Verily Life Sciences: Series D Funding Round
Verily Life Sciences has successfully raised $1B in Series D funding, reaching a valuation of $6B.
Company Overview
Precision health and life sciences research
Funding Details
The Series D round was led by Temasek, with participation from Silver Lake, Ontario Teachers.
Company Information
- Headquarters: South San Francisco, CA
- Founded: 2015
- Employees: 1500+
- Category: HealthTech
Investment
Verily Life Sciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Temasek: Verified investor in Series D
- Silver Lake: Verified investor in Series D
- Ontario Teachers: Verified investor in Series D
Key Investors
About the Author
Related Company Reports
Abridge Raises $150M Series C to Transform HealthTech
Abridge has secured $150M Series C in funding to accelerate growth and innovation in the healthtech sector. Medical AI scribe platform automatically documenting patient-provider conversations and generating clinical notes...
Innovaccer Raises $275M Series F to Transform HealthTech
Innovaccer has secured $275M Series F in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform unifying patient data and providing analytics for value-based care and population health manage...
Truveta Raises $95M Series B to Transform HealthTech
Truveta has secured $95M Series B in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform aggregating de-identified patient records to accelerate medical research and drug development...
